Published in J Virol on June 01, 2006
HIV-1 Vif, APOBEC, and intrinsic immunity. Retrovirology (2008) 3.72
APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog (2008) 2.60
Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G. Nucleic Acids Res (2007) 2.49
Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation. J Virol (2007) 2.47
APOBEC proteins and intrinsic resistance to HIV-1 infection. Philos Trans R Soc Lond B Biol Sci (2009) 2.40
The DNA deaminase activity of human APOBEC3G is required for Ty1, MusD, and human immunodeficiency virus type 1 restriction. J Virol (2008) 2.21
The artiodactyl APOBEC3 innate immune repertoire shows evidence for a multi-functional domain organization that existed in the ancestor of placental mammals. BMC Mol Biol (2008) 1.85
The interaction of APOBEC3G with human immunodeficiency virus type 1 nucleocapsid inhibits tRNA3Lys annealing to viral RNA. J Virol (2007) 1.74
Oligomerization transforms human APOBEC3G from an efficient enzyme to a slowly dissociating nucleic acid-binding protein. Nat Chem (2013) 1.65
Deaminase-independent inhibition of parvoviruses by the APOBEC3A cytidine deaminase. PLoS Pathog (2009) 1.65
An extended structure of the APOBEC3G catalytic domain suggests a unique holoenzyme model. J Mol Biol (2009) 1.62
Extensive mutagenesis experiments corroborate a structural model for the DNA deaminase domain of APOBEC3G. FEBS Lett (2007) 1.62
A model for oligomeric regulation of APOBEC3G cytosine deaminase-dependent restriction of HIV. J Biol Chem (2008) 1.62
Human immunodeficiency virus (HIV) type 1 proviral hypermutation correlates with CD4 count in HIV-infected women from Kenya. J Virol (2008) 1.53
Targeting APOBEC3A to the viral nucleoprotein complex confers antiviral activity. Retrovirology (2007) 1.52
Deamination-independent inhibition of hepatitis B virus reverse transcription by APOBEC3G. J Virol (2007) 1.52
Nanostructures of APOBEC3G support a hierarchical assembly model of high molecular mass ribonucleoprotein particles from dimeric subunits. J Biol Chem (2006) 1.50
Interactions of murine APOBEC3 and human APOBEC3G with murine leukemia viruses. J Virol (2008) 1.50
Analysis of the contribution of cellular and viral RNA to the packaging of APOBEC3G into HIV-1 virions. Retrovirology (2007) 1.48
The APOBEC3 family of retroelement restriction factors. Curr Top Microbiol Immunol (2013) 1.46
Evolutionarily conserved and non-conserved retrovirus restriction activities of artiodactyl APOBEC3F proteins. Nucleic Acids Res (2006) 1.46
APOBEC3F and APOBEC3G inhibit HIV-1 DNA integration by different mechanisms. J Virol (2010) 1.40
Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all. J Mol Biol (2013) 1.39
Atomic force microscopy studies provide direct evidence for dimerization of the HIV restriction factor APOBEC3G. J Biol Chem (2010) 1.38
Functions and regulation of the APOBEC family of proteins. Semin Cell Dev Biol (2011) 1.38
NMR structure of human restriction factor APOBEC3A reveals substrate binding and enzyme specificity. Nat Commun (2013) 1.36
Role of HIV-1 nucleocapsid protein in HIV-1 reverse transcription. RNA Biol (2010) 1.35
First-in-class small molecule inhibitors of the single-strand DNA cytosine deaminase APOBEC3G. ACS Chem Biol (2012) 1.28
Intracellular interactions between APOBEC3G, RNA, and HIV-1 Gag: APOBEC3G multimerization is dependent on its association with RNA. Retrovirology (2009) 1.27
Multiple ways of targeting APOBEC3-virion infectivity factor interactions for anti-HIV-1 drug development. Trends Pharmacol Sci (2009) 1.24
Two regions within the amino-terminal half of APOBEC3G cooperate to determine cytoplasmic localization. J Virol (2008) 1.24
Biochemical differentiation of APOBEC3F and APOBEC3G proteins associated with HIV-1 life cycle. J Biol Chem (2006) 1.19
T cells contain an RNase-insensitive inhibitor of APOBEC3G deaminase activity. PLoS Pathog (2007) 1.19
Single-stranded RNA facilitates nucleocapsid: APOBEC3G complex formation. RNA (2008) 1.19
Dissecting APOBEC3G substrate specificity by nucleoside analog interference. J Biol Chem (2009) 1.17
Stably expressed APOBEC3F has negligible antiviral activity. J Virol (2010) 1.15
Biochemical and biological studies of mouse APOBEC3. J Virol (2014) 1.14
The dimerization domain of HIV-1 viral infectivity factor Vif is required to block virion incorporation of APOBEC3G. Retrovirology (2007) 1.14
Tumultuous relationship between the human immunodeficiency virus type 1 viral infectivity factor (Vif) and the human APOBEC-3G and APOBEC-3F restriction factors. Microbiol Mol Biol Rev (2009) 1.12
HIV-1 Vif-mediated ubiquitination/degradation of APOBEC3G involves four critical lysine residues in its C-terminal domain. Proc Natl Acad Sci U S A (2009) 1.06
Functional domain organization of human APOBEC3G. Virology (2008) 1.03
HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors. Mol Aspects Med (2010) 1.03
Advances in the structural understanding of Vif proteins. Curr HIV Res (2008) 1.03
APOBEC3G: an intracellular centurion. Philos Trans R Soc Lond B Biol Sci (2009) 1.02
Structural determinants of human APOBEC3A enzymatic and nucleic acid binding properties. Nucleic Acids Res (2013) 1.01
Deaminase activity on single-stranded DNA (ssDNA) occurs in vitro when APOBEC3G cytidine deaminase forms homotetramers and higher-order complexes. J Biol Chem (2011) 1.00
Antiviral Mechanism and Biochemical Basis of the Human APOBEC3 Family. Front Microbiol (2012) 1.00
Suppression of APOBEC3-mediated restriction of HIV-1 by Vif. Front Microbiol (2014) 1.00
Nanoscale structure and dynamics of ABOBEC3G complexes with single-stranded DNA. Biochemistry (2012) 1.00
APOBEC3G and APOBEC3F require an endogenous cofactor to block HIV-1 replication. PLoS Pathog (2008) 0.99
Definition of the interacting interfaces of Apobec3G and HIV-1 Vif using MAPPIT mutagenesis analysis. Nucleic Acids Res (2009) 0.98
Phosphorylation directly regulates the intrinsic DNA cytidine deaminase activity of activation-induced deaminase and APOBEC3G protein. J Biol Chem (2011) 0.98
Mechanisms of base substitution mutagenesis in cancer genomes. Genes (Basel) (2014) 0.98
APOBEC3G: a double agent in defense. Trends Biochem Sci (2011) 0.96
The multifaceted roles of RNA binding in APOBEC cytidine deaminase functions. Wiley Interdiscip Rev RNA (2014) 0.94
AID and Apobec3G haphazard deamination and mutational diversity. Cell Mol Life Sci (2012) 0.93
APOBEC2 is a monomer in solution: implications for APOBEC3G models. Biochemistry (2012) 0.93
Multifaceted counter-APOBEC3G mechanisms employed by HIV-1 Vif. J Mol Biol (2011) 0.93
Binding of RNA by APOBEC3G controls deamination-independent restriction of retroviruses. Nucleic Acids Res (2013) 0.92
The ssDNA Mutator APOBEC3A Is Regulated by Cooperative Dimerization. Structure (2015) 0.92
Structural Insights into HIV-1 Vif-APOBEC3F Interaction. J Virol (2015) 0.91
APOBEC3 multimerization correlates with HIV-1 packaging and restriction activity in living cells. J Mol Biol (2013) 0.90
Quantification of deaminase activity-dependent and -independent restriction of HIV-1 replication mediated by APOBEC3F and APOBEC3G through experimental-mathematical investigation. J Virol (2014) 0.89
Promiscuous RNA binding ensures effective encapsidation of APOBEC3 proteins by HIV-1. PLoS Pathog (2015) 0.89
Leveraging APOBEC3 proteins to alter the HIV mutation rate and combat AIDS. Future Virol (2009) 0.89
Encapsidation of APOBEC3G into HIV-1 virions involves lipid raft association and does not correlate with APOBEC3G oligomerization. Retrovirology (2009) 0.89
Impact of H216 on the DNA binding and catalytic activities of the HIV restriction factor APOBEC3G. J Virol (2013) 0.88
Direct evidence that RNA inhibits APOBEC3G ssDNA cytidine deaminase activity. Biochem Biophys Res Commun (2011) 0.88
APOBEC3 proteins and genomic stability: the high cost of a good defense. Cell Cycle (2012) 0.88
APOBEC3G cytosine deamination hotspots are defined by both sequence context and single-stranded DNA secondary structure. Nucleic Acids Res (2013) 0.87
Association of potent human antiviral cytidine deaminases with 7SL RNA and viral RNP in HIV-1 virions. J Virol (2010) 0.87
Rationalisation of the differences between APOBEC3G structures from crystallography and NMR studies by molecular dynamics simulations. PLoS One (2010) 0.87
Retroviral restriction factor APOBEC3G delays the initiation of DNA synthesis by HIV-1 reverse transcriptase. PLoS One (2013) 0.86
A computational analysis of the structural determinants of APOBEC3's catalytic activity and vulnerability to HIV-1 Vif. Virology (2014) 0.86
A Comparison of Two Single-Stranded DNA Binding Models by Mutational Analysis of APOBEC3G. Biology (Basel) (2012) 0.85
Signals in APOBEC3F N-terminal and C-terminal deaminase domains each contribute to encapsidation in HIV-1 virions and are both required for HIV-1 restriction. J Biol Chem (2012) 0.84
Crystal structures of APOBEC3G N-domain alone and its complex with DNA. Nat Commun (2016) 0.83
The APOBEC Protein Family: United by Structure, Divergent in Function. Trends Biochem Sci (2016) 0.82
Sequence and structural determinants of human APOBEC3H deaminase and anti-HIV-1 activities. Retrovirology (2015) 0.80
APOBEC3G inhibits HIV-1 RNA elongation by inactivating the viral trans-activation response element. J Mol Biol (2014) 0.80
Lack of association between intact/deletion polymorphisms of the APOBEC3B gene and HIV-1 risk. PLoS One (2014) 0.80
6th international symposium on retroviral nucleocapsid. Retrovirology (2008) 0.79
RNA binding to APOBEC3G induces the disassembly of functional deaminase complexes by displacing single-stranded DNA substrates. Nucleic Acids Res (2015) 0.78
APOBEC3 inhibits DEAD-END function to regulate microRNA activity. BMC Mol Biol (2013) 0.77
Structural and functional assessment of APOBEC3G macromolecular complexes. Methods (2016) 0.77
The role of BST2/tetherin in feline retrovirus infection. Vet Immunol Immunopathol (2011) 0.77
APOBEC4 Enhances the Replication of HIV-1. PLoS One (2016) 0.76
APOBEC3 proteins can copackage and comutate HIV-1 genomes. Nucleic Acids Res (2016) 0.76
In vitro Assay for Cytidine Deaminase Activity of APOBEC3 Protein. Bio Protoc (2014) 0.75
Characterization of the Deamination Coupled with Sliding along DNA of Anti-HIV Factor APOBEC3G on the Basis of the pH-Dependence of Deamination Revealed by Real-Time NMR Monitoring. Front Microbiol (2016) 0.75
Free Energy Profile of APOBEC3G Protein Calculated by a Molecular Dynamics Simulation. Biology (Basel) (2012) 0.75
APOBEC3G-Mediated G-to-A Hypermutation of the HIV-1 Genome: The Missing Link in Antiviral Molecular Mechanisms. Front Microbiol (2016) 0.75
The double-domain cytidine deaminase APOBEC3G is a cellular site-specific RNA editing enzyme. Sci Rep (2016) 0.75
Structural determinants of APOBEC3B non-catalytic domain for molecular assembly and catalytic regulation. Nucleic Acids Res (2017) 0.75
Dimerization regulates both deaminase-dependent and deaminase-independent HIV-1 restriction by APOBEC3G. Nat Commun (2017) 0.75
Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature (2002) 21.53
Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature (2003) 13.24
DNA deamination mediates innate immunity to retroviral infection. Cell (2003) 12.10
Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science (2003) 10.79
The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature (2003) 10.76
The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med (2003) 9.22
HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat Med (2003) 8.40
The HIV 'A' (sor) gene product is essential for virus infectivity. Nature (1987) 7.51
HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol Cell (2003) 7.42
An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics (2002) 7.10
Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat Struct Mol Biol (2004) 6.26
Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science (2003) 6.20
The sor gene of HIV-1 is required for efficient virus transmission in vitro. Science (1987) 6.16
Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J Virol (1993) 6.11
Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes. J Virol (1992) 5.85
A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO J (2004) 5.67
The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr Biol (2003) 5.58
Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J Biol Chem (2003) 5.45
Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr Biol (2005) 4.98
DNA methylation in health and disease. Nat Rev Genet (2000) 4.58
The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity. J Virol (2003) 4.23
Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors. J Virol (2006) 3.63
Comparison of the differential context-dependence of DNA deamination by APOBEC enzymes: correlation with mutation spectra in vivo. J Mol Biol (2004) 3.59
Complementary function of the two catalytic domains of APOBEC3G. Virology (2005) 3.45
APOBEC3G incorporation into human immunodeficiency virus type 1 particles. J Virol (2004) 3.17
Efficiency of viral DNA synthesis during infection of permissive and nonpermissive cells with vif-negative human immunodeficiency virus type 1. J Virol (1993) 3.12
Messenger RNA editing in mammals: new members of the APOBEC family seeking roles in the family business. Trends Genet (2003) 3.11
Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs. J Biol Chem (2004) 3.01
Cell-dependent requirement of human immunodeficiency virus type 1 Vif protein for maturation of virus particles. J Virol (1993) 3.01
Nucleic acid chaperone activity of HIV-1 nucleocapsid protein: critical role in reverse transcription and molecular mechanism. Prog Nucleic Acid Res Mol Biol (2005) 2.98
Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor. Virology (2004) 2.75
The retroviral hypermutation specificity of APOBEC3F and APOBEC3G is governed by the C-terminal DNA cytosine deaminase domain. J Biol Chem (2005) 2.62
The enzymatic activity of CEM15/Apobec-3G is essential for the regulation of the infectivity of HIV-1 virion but not a sole determinant of its antiviral activity. J Biol Chem (2003) 2.59
Role of Vif in human immunodeficiency virus type 1 reverse transcription. J Virol (1996) 2.35
Viral RNA is required for the association of APOBEC3G with human immunodeficiency virus type 1 nucleoprotein complexes. J Virol (2005) 2.29
APOBEC3G is a single-stranded DNA cytidine deaminase and functions independently of HIV reverse transcriptase. Nucleic Acids Res (2004) 2.28
LuSIV cells: a reporter cell line for the detection and quantitation of a single cycle of HIV and SIV replication. Virology (2000) 2.07
Evolutionary origins of apoB mRNA editing: catalysis by a cytidine deaminase that has acquired a novel RNA-binding motif at its active site. Cell (1995) 1.86
Human immunodeficiency virus type 1 nucleocapsid protein reduces reverse transcriptase pausing at a secondary structure near the murine leukemia virus polypurine tract. J Virol (1996) 1.83
RNA editing: cytidine to uridine conversion in apolipoprotein B mRNA. Biochim Biophys Acta (2000) 1.77
Human immunodeficiency virus type 1 Vif does not influence expression or virion incorporation of gag-, pol-, and env-encoded proteins. J Virol (1996) 1.76
Death by deamination: a novel host restriction system for HIV-1. Cell (2003) 1.71
Monomeric APOBEC3G is catalytically active and has antiviral activity. J Virol (2006) 1.60
Is HIV-1 RNA dimerization a prerequisite for packaging? Yes, no, probably? Retrovirology (2004) 1.59
DNA deamination: not just a trigger for antibody diversification but also a mechanism for defense against retroviruses. Nat Immunol (2003) 1.54
Cytidine deamination and resistance to retroviral infection: towards a structural understanding of the APOBEC proteins. Virology (2005) 1.36
Virology. Weapons of mutational destruction. Science (2003) 1.19
Defects in primer-template binding, processive DNA synthesis, and RNase H activity associated with chimeric reverse transcriptases having the murine leukemia virus polymerase domain joined to Escherichia coli RNase H. Biochemistry (1995) 1.18
Incorporation of uracil into minus strand DNA affects the specificity of plus strand synthesis initiation during lentiviral reverse transcription. J Biol Chem (2002) 1.16
Production of infectious SIVagm from human cells requires functional inactivation but not viral exclusion of human APOBEC3G. J Biol Chem (2004) 1.05
HIV-1 Vif: counteracting innate antiretroviral defenses. Mol Ther (2003) 0.97
Cytosine nucleoside/nucleotide deaminases and apolipoprotein B mRNA editing. Trends Biochem Sci (1994) 0.91
The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity. J Virol (2003) 4.23
HIV-1 Vif, APOBEC, and intrinsic immunity. Retrovirology (2008) 3.72
Vpu enhances HIV-1 virus release in the absence of Bst-2 cell surface down-modulation and intracellular depletion. Proc Natl Acad Sci U S A (2009) 3.47
Viral protein U counteracts a human host cell restriction that inhibits HIV-1 particle production. Proc Natl Acad Sci U S A (2003) 3.05
A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion. Proc Natl Acad Sci U S A (2004) 2.99
Link between pericardial effusion and attenuation of QRS voltage in patients with hypothyroidism. Cardiology (2010) 2.81
Codon optimization of the HIV-1 vpu and vif genes stabilizes their mRNA and allows for highly efficient Rev-independent expression. Virology (2004) 2.80
Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G. Nucleic Acids Res (2007) 2.49
Viral RNA is required for the association of APOBEC3G with human immunodeficiency virus type 1 nucleoprotein complexes. J Virol (2005) 2.29
The formation of cysteine-linked dimers of BST-2/tetherin is important for inhibition of HIV-1 virus release but not for sensitivity to Vpu. Retrovirology (2009) 2.11
Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1. J Virol (2007) 2.03
Thiol/disulfide exchange is a prerequisite for CXCR4-tropic HIV-1 envelope-mediated T-cell fusion during viral entry. Blood (2003) 2.00
Guidelines for naming nonprimate APOBEC3 genes and proteins. J Virol (2008) 1.86
Multilayered mechanism of CD4 downregulation by HIV-1 Vpu involving distinct ER retention and ERAD targeting steps. PLoS Pathog (2010) 1.66
CD317/tetherin is enriched in the HIV-1 envelope and downregulated from the plasma membrane upon virus infection. J Virol (2010) 1.63
Monomeric APOBEC3G is catalytically active and has antiviral activity. J Virol (2006) 1.60
Restriction of virus infection but not catalytic dNTPase activity is regulated by phosphorylation of SAMHD1. J Virol (2013) 1.58
Biochemical and pathophysiological characterization of Helicobacter pylori asparaginase. Microbiol Immunol (2011) 1.56
Production of infectious human immunodeficiency virus type 1 does not require depletion of APOBEC3G from virus-producing cells. Retrovirology (2004) 1.56
Expression, purification, and activities of full-length and truncated versions of the integral membrane protein Vpu from HIV-1. Protein Sci (2002) 1.54
Human immunodeficiency virus type 1 Vif inhibits packaging and antiviral activity of a degradation-resistant APOBEC3G variant. J Virol (2007) 1.53
Targeting APOBEC3A to the viral nucleoprotein complex confers antiviral activity. Retrovirology (2007) 1.52
Broadening of CD8+ cell responses in vaccine-based simian immunodeficiency virus controllers. AIDS (2010) 1.52
Helicobacter pylori CagA status associated with gastric cancer incidence rate variability in Costa Rican regions. J Gastroenterol (2006) 1.49
Human immunodeficiency virus type 1 Vif is efficiently packaged into virions during productive but not chronic infection. J Virol (2003) 1.49
Analysis of the contribution of cellular and viral RNA to the packaging of APOBEC3G into HIV-1 virions. Retrovirology (2007) 1.48
Prognostic effect of lymph node micrometastasis in patients with histologically node-negative gastric cancer. Ann Surg Oncol (2002) 1.40
HIV-1 accessory proteins VPR and Vif modulate antiviral response by targeting IRF-3 for degradation. Virology (2007) 1.40
Subtle alterations of the native zinc finger structures have dramatic effects on the nucleic acid chaperone activity of human immunodeficiency virus type 1 nucleocapsid protein. J Virol (2002) 1.39
Gag-specific cytotoxic T-lymphocyte-based control of primary simian immunodeficiency virus replication in a vaccine trial. J Virol (2008) 1.38
Identification of amino acids in the human tetherin transmembrane domain responsible for HIV-1 Vpu interaction and susceptibility. J Virol (2010) 1.37
A case of transient left ventricular ballooning with pheochromocytoma, supporting pathogenetic role of catecholamines in stress-induced cardiomyopathy or takotsubo cardiomyopathy. Int J Cardiol (2006) 1.37
NMR structure of human restriction factor APOBEC3A reveals substrate binding and enzyme specificity. Nat Commun (2013) 1.36
High level expression of human immunodeficiency virus type-1 Vif inhibits viral infectivity by modulating proteolytic processing of the Gag precursor at the p2/nucleocapsid processing site. J Biol Chem (2004) 1.34
Naturally occurring amino acid substitutions in the HIV-2 ROD envelope glycoprotein regulate its ability to augment viral particle release. Virology (2003) 1.32
Chemical chaperones improve transport and enhance stability of mutant alpha-glucosidases in glycogen storage disease type II. Mol Genet Metab (2006) 1.26
Human immunodeficiency virus type 1 N-terminal capsid mutants containing cores with abnormally high levels of capsid protein and virtually no reverse transcriptase. J Virol (2003) 1.24
The HIV-1 Vpu protein: a multifunctional enhancer of viral particle release. Microbes Infect (2003) 1.24
Nucleic acid conformational changes essential for HIV-1 nucleocapsid protein-mediated inhibition of self-priming in minus-strand transfer. J Mol Biol (2003) 1.22
Stably expressed APOBEC3F has negligible antiviral activity. J Virol (2010) 1.15
Lymphomatosis cerebri: clinical characteristics, neuroimaging, and pathological findings. Brain Tumor Pathol (2011) 1.15
Expression of HIV-1 accessory protein Vif is controlled uniquely to be low and optimal by proteasome degradation. Microbes Infect (2004) 1.13
HIV-1 Vpu targets cell surface markers CD4 and BST-2 through distinct mechanisms. Mol Aspects Med (2010) 1.09
Differential effects of human immunodeficiency virus type 1 Vpu on the stability of BST-2/tetherin. J Virol (2010) 1.06
HIV-1 Vif-mediated ubiquitination/degradation of APOBEC3G involves four critical lysine residues in its C-terminal domain. Proc Natl Acad Sci U S A (2009) 1.06
Production of infectious SIVagm from human cells requires functional inactivation but not viral exclusion of human APOBEC3G. J Biol Chem (2004) 1.05
Species-specific insecticide resistance to imidacloprid and fipronil in the rice planthoppers Nilaparvata lugens and Sogatella furcifera in East and South-east Asia. Pest Manag Sci (2008) 1.05
Prognostic significance of microvessel density determined by an anti-CD105/endoglin monoclonal antibody in astrocytic tumors: comparison with an anti-CD31 monoclonal antibody. Neuropathology (2005) 1.05
A human immunodeficiency virus type 1 protease biosensor assay using bioluminescence resonance energy transfer. J Virol Methods (2005) 1.04
A case of transient 2:1 atrioventricular block, resolved by thyroxine supplementation for subclinical hypothyroidism. Pacing Clin Electrophysiol (2006) 1.03
HIV-1 Vif promotes the formation of high molecular mass APOBEC3G complexes. Virology (2007) 1.03
Adaptive evolution of Mus Apobec3 includes retroviral insertion and positive selection at two clusters of residues flanking the substrate groove. PLoS Pathog (2010) 1.03
Identification and characterization of naturally occurring splice variants of SAMHD1. Retrovirology (2012) 1.02
C-terminal hydrophobic region in human bone marrow stromal cell antigen 2 (BST-2)/tetherin protein functions as second transmembrane motif. J Biol Chem (2011) 1.01
Fundamental differences between the nucleic acid chaperone activities of HIV-1 nucleocapsid protein and Gag or Gag-derived proteins: biological implications. Virology (2010) 1.01
Effect of polypurine tract (PPT) mutations on human immunodeficiency virus type 1 replication: a virus with a completely randomized PPT retains low infectivity. J Virol (2005) 1.01
Structural determinants of human APOBEC3A enzymatic and nucleic acid binding properties. Nucleic Acids Res (2013) 1.01
Alteration of nucleic acid structure and stability modulates the efficiency of minus-strand transfer mediated by the HIV-1 nucleocapsid protein. J Biol Chem (2004) 1.01
Efficient initiation of HIV-1 reverse transcription in vitro. Requirement for RNA sequences downstream of the primer binding site abrogated by nucleocapsid protein-dependent primer-template interactions. J Biol Chem (2003) 1.00
Human immunodeficiency virus type 1 replication and regulation of APOBEC3G by peptidyl prolyl isomerase Pin1. J Virol (2008) 1.00
Identification of dominant negative human immunodeficiency virus type 1 Vif mutants that interfere with the functional inactivation of APOBEC3G by virus-encoded Vif. J Virol (2010) 1.00
A carboxy-terminally truncated human CPSF6 lacking residues encoded by exon 6 inhibits HIV-1 cDNA synthesis and promotes capsid disassembly. J Virol (2013) 0.99
The interdomain linker region of HIV-1 capsid protein is a critical determinant of proper core assembly and stability. Virology (2011) 0.99
The interferon-inducible host factor bone marrow stromal antigen 2/tetherin restricts virion release, but is it actually a viral restriction factor? J Interferon Cytokine Res (2010) 0.98
Production of infectious virus and degradation of APOBEC3G are separable functional properties of human immunodeficiency virus type 1 Vif. Virology (2007) 0.96
Prognostic significance of the immunohistochemical expression of O6-methylguanine-DNA methyltransferase, P-glycoprotein, and multidrug resistance protein-1 in glioblastomas. Neuropathology (2008) 0.95
Differential sensitivity of "old" versus "new" APOBEC3G to human immunodeficiency virus type 1 vif. J Virol (2008) 0.94
Pathology of intracranial germ cell tumors. Prog Neurol Surg (2009) 0.94
Serum pepsinogen levels, Helicobacter pylori CagA Status, and cytokine gene polymorphisms associated with gastric premalignant lesions in Costa Rica. Cancer Epidemiol Biomarkers Prev (2007) 0.93
Absence of orbito-ocular signs in dural carotid-cavernous sinus fistula with a prominent anterior venous drainage. J Neurol Sci (2005) 0.93
Expression of vascular endothelial growth factor-A and mRNA stability factor HuR in human astrocytic tumors. Neuropathology (2008) 0.92
Astroblastoma: immunohistochemical and ultrastructural study of distinctive epithelial and probable tanycytic differentiation. Neuropathology (2006) 0.92
A new diagnostic assay for glycogen storage disease type II in mixed leukocytes. Mol Genet Metab (2005) 0.92
Human immunodeficiency virus type 2 reverse transcriptase activity in model systems that mimic steps in reverse transcription. J Virol (2003) 0.92
APOBEC3G-independent reduction in virion infectivity during long-term HIV-1 replication in terminally differentiated macrophages. Virology (2008) 0.91
Intravirion processing of the human immunodeficiency virus type 1 Vif protein by the viral protease may be correlated with Vif function. J Virol (2002) 0.91
Vif counteracts a cyclophilin A-imposed inhibition of simian immunodeficiency viruses in human cells. J Virol (2007) 0.91
Role of bacterial and genetic factors in gastric cancer in Costa Rica. World J Gastroenterol (2009) 0.91
Tissue characterization of glioma by proton magnetic resonance spectroscopy and perfusion-weighted magnetic resonance imaging: glioma grading and histological correlation. Clin Imaging (2008) 0.90
Successful removal after radiotherapy and vascular embolization in a huge tentorial epithelioid hemangioendothelioma: a case report. J Neurooncol (2004) 0.90
Grading of brain glioma with 1-11C-acetate PET: comparison with 18F-FDG PET. Nucl Med Biol (2008) 0.90
Length of laparotomy incision and surgical stress assessed by serum IL-6 level. Injury (2006) 0.90
Nestin expression in astrocytic tumors delineates tumor infiltration. Brain Tumor Pathol (2010) 0.89
Effects of nucleic acid local structure and magnesium ions on minus-strand transfer mediated by the nucleic acid chaperone activity of HIV-1 nucleocapsid protein. Nucleic Acids Res (2007) 0.89
Encapsidation of APOBEC3G into HIV-1 virions involves lipid raft association and does not correlate with APOBEC3G oligomerization. Retrovirology (2009) 0.89
Carbonic anhydrase inhibitors: DNA cloning and inhibition studies of the alpha-carbonic anhydrase from Helicobacter pylori, a new target for developing sulfonamide and sulfamate gastric drugs. J Med Chem (2006) 0.89
Expression of vascular endothelial growth factor-A and mRNA stability factor HuR in human meningiomas. J Neurooncol (2008) 0.89
Helicobacter pylori-associated chronic idiopathic thrombocytopenic purpura and low molecular weight H. pylori proteins. Scand J Infect Dis (2007) 0.88